Drug intelligence / Profile preview

MFA 031

Development stage: Preclinical
Lead developer: MediMabBio
Modality: Antibody Conjugates → Antibody-Based Therapeutics
Administration: Parenteral

Overview

MFA 031 is a neutralizing monoclonal antibody developed by MediMabBio for the treatment of autoimmune diseases. It functions as an immunomodulator by inhibiting GITR (Glucocorticoid-induced tumor necrosis factor receptor-related protein), a target involved in immune system regulation. The drug is currently in preclinical development and is being investigated primarily for autoimmune disorders[1][2][5].

Targets

TNFRSF18 (GITR)

Beyond the preview

Go deeper on MFA 031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MFA 031.

Explore the full profile